Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Mustika Ratu Tbk, (MRAT) Fair Value & Analysis

Consumer Defensive · ID · Market cap 178B IDR

Price450.00 IDR
Fair Value282.83 IDR
Upside-37.1%
Quality85/100
Evidence: Medium Range 184.80 IDR – 430.66 IDR

Fair value as of: Jun 24, 2026

Analysis

PT Mustika Ratu Tbk, (MRAT) currently trades at 450.00 IDR, while our model-based Fair Value estimate is 282.83 IDR — implying the stock looks roughly 37.1% overvalued today. We read business quality at 85/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

PT Mustika Ratu Tbk, together with its subsidiaries, engages in the manufacture, trade, and distribution of herbal medicine and traditional cosmetics in Indonesia. It is also involved in entertainment activities. The company was founded in 1978 and is based in Jakarta Selatan, Indonesia. PT Mustika Ratu Tbk operates as a subsidiary of PT Mustika Ratu Investama.

Open the full interactive analysis →

Similar stocks

The Procter & Gamble Company (PG) -26% L'Oréal S.A (LRLCF) -38% Unilever PLC (UNLYF) -22% Colgate-Palmolive Company (CPA) -29% Hindustan Unilever Limited (HINDUNILVR) -68% Reckitt Benckiser Group (RBGLY) +41%

Frequently asked questions

Is PT Mustika Ratu Tbk, (MRAT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 282.83 IDR versus a price of 450.00 IDR — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MRAT?
Our 21-model fair value for PT Mustika Ratu Tbk, is 282.83 IDR (as of Jun 24, 2026), built from audited fundamentals. The current price is 450.00 IDR.
What is the quality score of MRAT?
PT Mustika Ratu Tbk, has a Quality Score of 85/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.